newswire, breaking biotechnology and pharma news

Friday, May 11, 2012

Biopharmaceutical Stock to Watch; Arena Pharmaceuticals (NASDAQ:ARNA) Big Moves on Lorcaserin Obesity Drug

New York, New York - May 11, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) making big moves, gaining $5.82 2.16(59.02%) 10:51AM EDT on over 40 million shares in morning trading . The stock was up over 80% during earlier trading.
Arena Pharmaceuticals, Inc. (ARNA) and Eisai Inc. reported yesterday, the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management. In addition to the United States, the territories in the expanded agreement now include most of North and South America, including Canada, Mexico and Brazil. This expansion builds on the agreement executed by Eisai and Arena in July 2010 for Eisai's exclusive rights to market and distribute lorcaserin in the United States, subject to lorcaserin's approval by the US Food and Drug Administration (FDA). Newswire About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow on Twitter!/ Investorideas
Follow on Facebook Investorideas
Sign up for the free investor news and stock alerts
Research biotech stocks at the Biotech stocks Directory:
Become an Member
Follow on Twitter!/Investorideas
Follow on Facebook
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
Source -

No comments:

Post a Comment